Genentech Announces Phase III Study Results for Tecentriq Plus Cotellic and Zelboraf in People With Previously Untreated BRAF V600 Mutationpositive Advanced Melanoma

Genentech a member of the Roche Group SIX RO ROG; OTCQX RHHBY today announced the Phase III IMspire150 study in people with previously untreated BRAF V600 mutationpositive advanced melanoma met its primary endpoint of progressionfree survival PFS. The stud...